Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage	$ (30,464,000)	$ (5,760,000)	$ (34,603,000)	$ (12,302,000)
Net income (loss) attributable to noncontrolling interest	100,000	(13,000)	96,000	(29,000)
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Issuance costs for common stock warrant liabilities			183,000	0
Loss on impairment of intangible asset	14,840,000	0	14,840,000	0
Loss on marketable equity securities, net	2,000	10,000	7,000	15,000
Accretion of income on marketable debt securities			(10,000)	(102,000)
Depreciation and amortization expense	171,000	142,000	335,000	295,000
Change in right-of-use assets and liabilities			(88,000)	(20,000)
Amortization of intangible assets			0	22,000
Stock-based compensation			2,455,000	2,432,000
Change in fair value of warrant liability	12,740,000	0	10,435,000	0
Foreign currency remeasurement and other loss			(1,455,000)	767,000
Changes in operating assets and liabilities:
Accounts receivable			381,000	508,000
Prepaid expenses and other current assets			1,271,000	516,000
Accounts payable and accrued liabilities			(459,000)	(1,245,000)
Deferred revenue			(3,813,000)	(1,816,000)
Net cash used in operating activities			(10,425,000)	(10,959,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of marketable equity securities			0	18,000
Purchases of marketable debt securities			0	(8,761,000)
Maturities of marketable debt securities			2,000,000	0
Purchase of equipment			(111,000)	(88,000)
Net cash (used in) provided by investing activities			1,889,000	(8,831,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from employee options exercised			0	219,000
Common shares received and retired for employee taxes paid			(15,000)	(23,000)
Payment of financed insurance premium			(452,000)	0
Payment of finance lease liabilities			(28,000)	(27,000)
Net cash provided by financing activities			4,737,000	14,126,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash			220,000	(158,000)
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(3,579,000)	(5,822,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period			46,354,000	35,992,000
At end of the period	42,775,000	30,170,000	42,775,000	30,170,000
SUPPLEMENTAL DISCLOSURES
Cash paid for interest			23,000	4,000
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES:
Property and equipment expenditures in accounts payable			1,000	58,000
Fair value of warrant liability recognized upon issuance in registered direct financing			2,205,000	0
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	42,271,000	29,622,000	42,271,000	29,622,000
Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))	504,000	548,000	504,000	548,000
Total cash, cash equivalents, and restricted cash	$ 42,775,000	$ 30,170,000	42,775,000	30,170,000
ATM [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs			0	68,000
Direct Financing [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs			0	13,889,000
Warrants Under Registered Direct Financing [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs			$ 5,232,000	$ 0